Director/PDMR Shareholding

RNS Number : 5836Y
Dechra Pharmaceuticals PLC
09 September 2015
 





 

 

 

9 September 2015

 

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

 

Director shareholding

 

Exercise of option:

 

Dechra Pharmaceuticals PLC announces that on 8 September 2015, Anne-Francoise Nesmes, Chief Financial Officer, exercised a nil cost option over ordinary shares of 1p each in the Company. The option was granted to her on 27 September 2013 as part of the recruitment award referred to in the Company's Directors' Remuneration Report for the year ended 30 June 2014.

 

Anne-Francoise Nesmes sold sufficient shares (acquired pursuant to the exercise) on 8 September 2015 in order to fund the resulting tax liability. 

 

 

Options Exercised

Shares Sold

Sale Price

per share

 

Total beneficial shareholding following this announcement

Percentage of issued share capital

38,859

18,319

£9.40

42,602

0.048%

 

The exercise of the option was subject to a performance review, as a result of which the vesting percentage is 93.1%. The shares have been transferred to her spouse, Jeramy Rankine, for nil consideration. Following this transfer, Anne-Francoise Nesmes's beneficial interest in the Company remains unchanged, being 42,602 shares, which represents 0.048% of the current issued share capital.

 

For further information, please contact:

 

Rob Lamb, Company Secretary          

Telephone number: 01606 814730

 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSPKCDKQBKDOCK
UK 100

Latest directors dealings